VIMPAT® (lacosamide) Patent Survives IPR Challenge April 25, 2017 The PTAB upheld the validity of Patent RE38,551 E (“the ’551 patent”), which covers VIMPAT® (lacosamide). See PTAB Litigation Blog by Jones Day, LLP: “Pharmaceutical Compound Nonobvious Absent Evidence Suggesting Specific Modification to Prior Art Compound” IPR2016-00204 Share: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Share on LinkedIn (Opens in new window) LinkedIn Print (Opens in new window) Print STIVARGA® (regorafenib) Survives Challenge at PTAB: Difference = One FluorineDateFebruary 9, 2017In relation toCase LawOnglyza® and Kombiglyze® XR (saxagliptin) Patent Survives Challenge from MylanDateSeptember 9, 2017In relation toCase LawPTAB Denies Amneal’s Request to Institute IPR Against Hospira’s Dexmedetomidine Pharmaceutical Composition PatentDateFebruary 6, 2017In relation toCase Law
